Our results indicate that anti-SMN antibodies may serve as a useful biomarker for disease stratification, assessment of disease activity and organ involvement, and prediction of relapse and prognosis in patients with SLE, in addition to those with MCTD. This evidence concerns the gene SMN1 and mixed connective tissue disease.